Sun Pharma Advanced Research Co (BOM:532872) Cash And Cash Equivalents : ₹19.6 Mil (As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Sun Pharma Advanced Research Co Cash And Cash Equivalents?

Sun Pharma Advanced Research Co's quarterly cash and cash equivalents stayed the same from Sep. 2024 (₹0.00 Mil) to Dec. 2024 (₹0.00 Mil) but then increased from Dec. 2024 (₹0.00 Mil) to Mar. 2025 (₹19.60 Mil).

Sun Pharma Advanced Research Co's annual cash and cash equivalents increased from Mar. 2023 (₹5.84 Mil) to Mar. 2024 (₹53.30 Mil) but then declined from Mar. 2024 (₹53.30 Mil) to Mar. 2025 (₹19.60 Mil).

Sun Pharma Advanced Research Co Cash And Cash Equivalents Historical Data

The historical data trend for Sun Pharma Advanced Research Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Pharma Advanced Research Co Cash And Cash Equivalents Chart

Sun Pharma Advanced Research Co Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Cash And Cash Equivalents

Get a 7-Day Free Trial

93.05

12.24

5.84

53.30

19.60

Sun Pharma Advanced Research Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															53.30	-	-	-	19.60

Sun Pharma Advanced Research Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Sun Pharma Advanced Research Co (BOM:532872) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Sun Pharma Advanced Research Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Sun Pharma Advanced Research Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Pharma Advanced Research Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharma Advanced Research Co Ltd (BOM:532872) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

SPARC:India

Address

Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093

Website

https://www.sparc.life

Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in othe4r countries.

Sun Pharma Advanced Research Co Headlines

No Headlines